Literature DB >> 26034172

Bruton's Tyrosine Kinase Synergizes with Notch2 To Govern Marginal Zone B Cells in Nonobese Diabetic Mice.

James B Case1,2, Rachel H Bonami1, Lindsay E Nyhoff2, Hannah E Steinberg1, Allison M Sullivan1, Peggy L Kendall1,2.   

Abstract

Expansion of autoimmune-prone marginal zone (MZ) B cells has been implicated in type 1 diabetes. To test disease contributions of MZ B cells in NOD mice, Notch2 haploinsufficiency (Notch2(+/-)) was introduced but failed to eliminate the MZ, as it does in C57BL/6 mice. Notch2(+/-)/NOD have MZ B cell numbers similar to those of wild-type C57BL/6, yet still develop diabetes. To test whether BCR signaling supports Notch2(+/-)/NOD MZ B cells, Bruton's tyrosine kinase (Btk) deficiency was introduced. Surprisingly, MZ B cells failed to develop in Btk-deficient Notch2(+/-)/NOD mice. Expression of Notch2 and its transcriptional target, Hes5, was increased in NOD MZ B cells compared with C57BL/6 MZ B cells. Btk deficiency reduced Notch2(+/-) signaling exclusively in NOD B cells, suggesting that BCR signaling enhances Notch2 signaling in this autoimmune model. The role of BCR signaling was further investigated using an anti-insulin transgenic (Tg) BCR (125Tg). Anti-insulin B cells in 125Tg/Notch2(+/-)/NOD mice populate an enlarged MZ, suggesting that low-level BCR signaling overcomes reliance on Notch2. Tracking clonotypes of anti-insulin B cells in H chain-only VH125Tg/NOD mice showed that BTK-dependent selection into the MZ depends on strength of antigenic binding, whereas Notch2-mediated selection does not. Importantly, anti-insulin B cell numbers were reduced by Btk deficiency, but not Notch2 haploinsufficiency. These studies show that 1) Notch2 haploinsufficiency limits NOD MZ B cell expansion without preventing type 1 diabetes, 2) BTK supports the Notch2 pathway in NOD MZ B cells, and 3) autoreactive NOD B cell survival relies on BTK more than Notch2, regardless of MZ location, which may have important implications for disease-intervention strategies.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26034172      PMCID: PMC4551465          DOI: 10.4049/jimmunol.1400803

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival.

Authors:  Jian Song; Zerina Lokmic; Tim Lämmermann; Julia Rolf; Chuan Wu; Xueli Zhang; Rupert Hallmann; Melanie-Jane Hannocks; Nathalie Horn; Markus A Ruegg; Arnoud Sonnenberg; Elisabeth Georges-Labouesse; Thomas H Winkler; John F Kearney; Susanna Cardell; Lydia Sorokin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-11       Impact factor: 11.205

2.  Intrinsic molecular factors cause aberrant expansion of the splenic marginal zone B cell population in nonobese diabetic mice.

Authors:  Jessica Stolp; Eliana Mariño; Marcel Batten; Frederic Sierro; Selwyn L Cox; Shane T Grey; Pablo A Silveira
Journal:  J Immunol       Date:  2013-06-05       Impact factor: 5.422

3.  CD19-independent instruction of murine marginal zone B-cell development by constitutive Notch2 signaling.

Authors:  Franziska Hampel; Stefanie Ehrenberg; Caroline Hojer; Anne Draeseke; Gabriele Marschall-Schröter; Ralf Kühn; Brigitte Mack; Olivier Gires; Christoph J Vahl; Marc Schmidt-Supprian; Lothar J Strobl; Ursula Zimber-Strobl
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

4.  Vkappa polymorphisms in NOD mice are spread throughout the entire immunoglobulin kappa locus and are shared by other autoimmune strains.

Authors:  Rachel A Henry; Peggy L Kendall; Emily J Woodward; Chrys Hulbert; James W Thomas
Journal:  Immunogenetics       Date:  2010-06-17       Impact factor: 2.846

5.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

Authors:  Yibin Yang; Arthur L Shaffer; N C Tolga Emre; Michele Ceribelli; Meili Zhang; George Wright; Wenming Xiao; John Powell; John Platig; Holger Kohlhammer; Ryan M Young; Hong Zhao; Yandan Yang; Weihong Xu; Joseph J Buggy; Sriram Balasubramanian; Lesley A Mathews; Paul Shinn; Rajarshi Guha; Marc Ferrer; Craig Thomas; Thomas A Waldmann; Louis M Staudt
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

6.  Lunatic and manic fringe cooperatively enhance marginal zone B cell precursor competition for delta-like 1 in splenic endothelial niches.

Authors:  Joanne B Tan; Keli Xu; Kira Cretegny; Ioana Visan; Julie S Yuan; Sean E Egan; Cynthia J Guidos
Journal:  Immunity       Date:  2009-02-12       Impact factor: 31.745

7.  B lymphocyte "original sin" in the bone marrow enhances islet autoreactivity in type 1 diabetes-prone nonobese diabetic mice.

Authors:  Rachel A Henry-Bonami; Jonathan M Williams; Amita B Rachakonda; Mariam Karamali; Peggy L Kendall; James W Thomas
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

8.  Generation of B cell memory to the bacterial polysaccharide alpha-1,3 dextran.

Authors:  Jeremy B Foote; John F Kearney
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

9.  Insulinoma-released exosomes activate autoreactive marginal zone-like B cells that expand endogenously in prediabetic NOD mice.

Authors:  Roman Bashratyan; Huiming Sheng; Danielle Regn; M Jubayer Rahman; Yang D Dai
Journal:  Eur J Immunol       Date:  2013-08-01       Impact factor: 5.532

10.  Notch-RBP-J-independent marginal zone B cell development in IgH transgenic mice with VH derived from a natural polyreactive antibody.

Authors:  Zhuo Zhang; Lanhua Zhou; Xinwei Yang; Yaochun Wang; Ping Zhang; Lihong Hou; Xinbin Hu; Ying Xing; Yufeng Liu; Wei Li; Hua Han
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

View more
  6 in total

1.  Anti-Insulin B Cells Are Poised for Antigen Presentation in Type 1 Diabetes.

Authors:  Jamie L Felton; Damian Maseda; Rachel H Bonami; Chrys Hulbert; James W Thomas
Journal:  J Immunol       Date:  2018-06-27       Impact factor: 5.422

Review 2.  The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.

Authors:  Leslie J Crofford; Lindsay E Nyhoff; Jonathan H Sheehan; Peggy L Kendall
Journal:  Expert Rev Clin Immunol       Date:  2016-03-04       Impact factor: 4.473

3.  Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.

Authors:  Lindsay E Nyhoff; Bridgette L Barron; Elizabeth M Johnson; Rachel H Bonami; Damian Maseda; Benjamin A Fensterheim; Wei Han; Timothy S Blackwell; Leslie J Crofford; Peggy L Kendall
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

4.  New Players in the Field of T1D: Anti-Peripherin B Lymphocytes.

Authors:  Peggy L Kendall
Journal:  Diabetes       Date:  2016-07       Impact factor: 9.461

Review 5.  Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.

Authors:  Anne B Satterthwaite
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

Review 6.  Notch Signaling in B Cell Immune Responses.

Authors:  Matthew Garis; Lee Ann Garrett-Sinha
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.